An original 2026 ASCO abstract describes PIN-5018 as an oral CRBN-mediated CK1α molecular glue. The first Phase 1 cohort completed without DLTs; subsequent cohorts are enrolling.
2026-08-21 · Series C follow-on financing (partly funded) · KRW 16.5 billion funded (as of July 2026) ↗
The full target was KRW 17 billion. The CEO stated that the first phase had closed and an expansion was under consideration; the full round was still expected to close within 2–3 months.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
An original 2026 ASCO abstract describes PIN-5018 as an oral CRBN-mediated CK1α molecular glue. The first Phase 1 cohort completed without DLTs; subsequent cohorts are enrolling.
A Korean official participant portal lists Phase 1 and a July 2026 update.
Program / service
Target / indication
Representative stage
Evidence & scope
PIN-5018
CK1α · See individual trial / indication; not individually confirmed in this review
Phase 1
Human results reported by the source; see facts and original materials for type and quality
Related news & literature
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
No cataloged update explicitly mentions this company.
A Nature Materials study describes mRNA-loaded LNPs that reprogram tumor-associated macrophages into Claudin18.2-targeting CAR macrophages. The lipid formulation also promotes TREM2 internalization and degradation, reshaping immune responses. The original abstract reports tumor suppression and longer survival with PD-1 blockade in mice, plus ex vivo patient-sample findings. These findings do not demonstrate clinical efficacy in treated patients.
A Frontiers in Pharmacology review compares direct MCL-1 inhibition with approaches that reduce its abundance, including transcriptional interventions and targeted degradation. The original abstract highlights limited single-agent activity and cardiac safety concerns with inhibitors, while positioning degradation as an unvalidated clinical strategy. Biomarker-guided combinations and dynamic BH3 profiling are discussed; this review does not report a new clinical trial.
Evommune licensed EVO570, formerly HC118, from Hinova for development and commercialization outside Greater China. Upfront consideration totals $30 million: $20 million cash and $10 million in pre-funded warrants. Additional development, regulatory, and commercial milestones could reach approximately $1.1 billion, plus royalties. Phase 1 was expected to begin shortly; the announcement does not establish human efficacy.
Research this company together
Discussions are for signed-in members. Personal notes remain separate from company research.
